Politics
The defeat of Question 4 in Massachusetts and the right wing mandate carried forward by voters increases uncertainty for policies that support access to psychedelics.
Massachusetts voters consider The Natural Psychedelic Substances Act which would legalize the possession and cultivation of certain psychedelics.
The Drug Enforcement Administration has released two notices in the Federal Register declaring plans over the next year to expand the production of psilocybin, psilocin, and ibogaine for use in new research and clinical trials.
Prior to last week’s FDA decision to reject Lykos Therapeutics’ proposed MDMA-assisted therapy for PTSD, Rep. Jack Bergman (R-MI) reflected on the urgent need for better PTSD treatments to reduce veteran suicides and the game plan for lawmakers to keep support for psychedelic-assisted therapies moving forward.
80 members of Congress sign letters of support for MDMA-AT, including those from states with psychedelic access on the ballot.
Final revisions to the proposed Psychedelic Wellness & Healing Initiative submitted yesterday would allow the sale, possession and use of psychedelics for medicinal and therapeutic purposes.
A Kentucky commission will soon vote on whether to commit $42 million toward a psychedelic-assisted therapy moonshot that could transform treatment for opioid use disorder nationally.
The bill, SB 58, includes a workgroup to propose facilitated use and now goes to Governor Newsom’s desk for signature.
Amendments to SB-58 would delay therapeutic and facilitated use of psychedelics in California until a regulatory framework similar to those in Oregon and Colorado is developed.
A statewide proposal, if passed, will allocate settlement funds from lawsuits against corporations involved in the opioid crisis towards research into ibogaine, which has demonstrated potential to treat opioid use disorder.
